Get the Stockscreener App
716.70
1.66%
12.39
Regeneron Pharmaceuticals Inc stock is traded at $716.70, with a volume of 409.83K.
It is up +1.66% in the last 24 hours and up +23.86% over the past month.
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including low-dose Eylea and Eylea HD, approved for wet age-related macular degeneration and other eye diseases; Dupixent in immunology; Praluent for LDL cholesterol lowering; Libtayo in oncology; and Kevzara in rheumatoid arthritis. Regeneron is also developing monoclonal and bispecific antibodies with Sanofi, other collaborators, and independently, and has early-stage partnerships that bring new technology to the pipeline, including RNAi (Alnylam) and Crispr-based gene editing (Intellia).
See More
Previous Close:
$704.31
Open:
$702.51
24h Volume:
409.83K
Relative Volume:
0.40
Market Cap:
$38.55B
Revenue:
$14.25B
Net Income/Loss:
$4.58B
P/E Ratio:
17.16
EPS:
41.7701
Net Cash Flow:
$3.88B
1W Performance:
+6.14%
1M Performance:
+23.86%
6M Performance:
+20.47%
1Y Performance:
-6.04%
1-Day Range:
$699.22
$717.16
1-Week Range:
$672.67
$716.99
52-Week Range:
$476.49
$800.99
Regeneron Pharmaceuticals Inc Stock (REGN) Company Profile
Name
Regeneron Pharmaceuticals Inc
Sector
Industry
Phone
(914) 847-7000
Address
777 OLD SAW MILL RIVER ROAD, TARRYTOWN, NY
Compare REGN with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
REGN
Regeneron Pharmaceuticals Inc
|
716.47 | 74.02B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
917.31 | 57.24B | 3.06B | 1.28B | 447.35M | 19.67 |
|
VRTX
Vertex Pharmaceuticals Inc
|
436.45 | 110.12B | 11.74B | 3.68B | 3.34B | 14.19 |
|
INSM
Insmed Inc
|
199.26 | 42.10B | 447.02M | -1.18B | -906.14M | -6.1812 |
|
ONC
Beone Medicines Ltd Adr
|
364.34 | 41.68B | 4.98B | 69.59M | 525.67M | 0.5197 |
Regeneron Pharmaceuticals Inc Stock (REGN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-13-25 | Initiated | Scotiabank | Sector Perform |
| Aug-14-25 | Initiated | Rothschild & Co Redburn | Buy |
| Jun-30-25 | Downgrade | Argus | Buy → Hold |
| May-30-25 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| May-30-25 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| May-14-25 | Upgrade | Citigroup | Neutral → Buy |
| Apr-22-25 | Resumed | Cantor Fitzgerald | Overweight |
| Feb-05-25 | Upgrade | Leerink Partners | Market Perform → Outperform |
| Jan-16-25 | Downgrade | UBS | Buy → Neutral |
| Dec-10-24 | Resumed | BofA Securities | Underperform |
| Nov-15-24 | Initiated | Wolfe Research | Outperform |
| Nov-14-24 | Initiated | Citigroup | Neutral |
| Sep-24-24 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Mar-12-24 | Initiated | Bernstein | Outperform |
| Jan-12-24 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Nov-09-23 | Initiated | Deutsche Bank | Hold |
| Nov-03-23 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Aug-21-23 | Upgrade | Canaccord Genuity | Hold → Buy |
| Aug-21-23 | Reiterated | Oppenheimer | Perform |
| Jun-28-23 | Downgrade | Canaccord Genuity | Buy → Hold |
| Mar-27-23 | Upgrade | SVB Securities | Market Perform → Outperform |
| Mar-24-23 | Upgrade | Jefferies | Hold → Buy |
| Mar-23-23 | Upgrade | Raymond James | Underperform → Mkt Perform |
| Jan-30-23 | Upgrade | Cowen | Market Perform → Outperform |
| Jan-20-23 | Upgrade | JP Morgan | Neutral → Overweight |
| Oct-26-22 | Downgrade | Raymond James | Mkt Perform → Underperform |
| Oct-17-22 | Downgrade | Evercore ISI | Outperform → In-line |
| Sep-09-22 | Upgrade | Jefferies | Underperform → Hold |
| Sep-09-22 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Jul-25-22 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| Jul-13-22 | Initiated | Cantor Fitzgerald | Neutral |
| Jun-06-22 | Initiated | Jefferies | Underperform |
| May-23-22 | Initiated | SVB Leerink | Outperform |
| Jan-05-22 | Downgrade | BofA Securities | Neutral → Underperform |
| Jan-03-22 | Upgrade | Bernstein | Mkt Perform → Outperform |
| Dec-15-21 | Downgrade | Bernstein | Outperform → Mkt Perform |
| Dec-09-21 | Resumed | Wells Fargo | Overweight |
| Dec-07-21 | Resumed | Cowen | Market Perform |
| Dec-06-21 | Initiated | Goldman | Buy |
| Nov-19-21 | Resumed | BMO Capital Markets | Outperform |
| Nov-05-21 | Downgrade | The Benchmark Company | Buy → Hold |
| Jun-29-21 | Initiated | H.C. Wainwright | Buy |
| Jan-25-21 | Upgrade | BMO Capital Markets | Market Perform → Outperform |
| Jan-13-21 | Upgrade | The Benchmark Company | Hold → Buy |
| Jan-08-21 | Upgrade | Citigroup | Neutral → Buy |
| Oct-05-20 | Upgrade | Cantor Fitzgerald | Neutral → Overweight |
| Aug-20-20 | Downgrade | The Benchmark Company | Buy → Hold |
| Jul-09-20 | Upgrade | SunTrust | Hold → Buy |
| May-26-20 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Apr-28-20 | Downgrade | Citigroup | Buy → Neutral |
| Apr-17-20 | Upgrade | The Benchmark Company | Hold → Buy |
| Apr-08-20 | Initiated | The Benchmark Company | Hold |
| Mar-31-20 | Initiated | Wolfe Research | Peer Perform |
| Feb-27-20 | Initiated | Barclays | Overweight |
| Feb-26-20 | Upgrade | Canaccord Genuity | Hold → Buy |
| Feb-26-20 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Feb-25-20 | Upgrade | Jefferies | Hold → Buy |
| Feb-11-20 | Upgrade | Argus | Hold → Buy |
| Dec-24-19 | Initiated | Raymond James | Mkt Perform |
| Dec-16-19 | Downgrade | Evercore ISI | Outperform → In-line |
| Dec-13-19 | Upgrade | Credit Suisse | Neutral → Outperform |
| Nov-12-19 | Initiated | SunTrust | Hold |
| Nov-07-19 | Upgrade | Citigroup | Neutral → Buy |
| Oct-17-19 | Resumed | BofA/Merrill | Neutral |
| Sep-23-19 | Upgrade | Guggenheim | Neutral → Buy |
View All
Regeneron Pharmaceuticals Inc Stock (REGN) Latest News
REGN: Eylea HD growth, label updates, and strategic capital deployment drive future outlook - TradingView
How Regeneron Pharmaceuticals Inc. (RGO) stock responds to job market shiftsMarket Risk Summary & Entry Point Strategy Guides - newser.com
Chronic Obstructive Pulmonary Disease Market Forecast - openPR.com
Regeneron at Jefferies London: Strategic Growth and Challenges - Investing.com
Regeneron at Wolfe Research Conference: Oncology Pipeline Insights - Investing.com
Westwood Holdings Group Inc. Grows Stock Holdings in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Persistent Asset Partners Ltd Sells 5,625 Shares of Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Commonwealth of Pennsylvania Public School Empls Retrmt SYS Boosts Stake in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Can Regeneron Pharmaceuticals Inc. stock hit record highs again2025 Breakouts & Breakdowns & Fast Entry and Exit Trade Plans - newser.com
Regeneron Pharmaceuticals, Inc. $REGN Shares Sold by Sculati Wealth Management LLC - MarketBeat
Can a trend reversal in Regeneron Pharmaceuticals Inc. lead to recoveryJuly 2025 Decliners & Long-Term Growth Plans - newser.com
Regeneron Pharmaceuticals to invest in new Saratoga Springs facility - The Post Star
How robust is Regeneron Pharmaceuticals Inc. (RGO) stock financial positionJuly 2025 Trends & Short-Term Swing Trade Alerts - newser.com
Savant Capital LLC Sells 2,607 Shares of Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Campbell & CO Investment Adviser LLC Buys Shares of 1,345 Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Why Regeneron Pharmaceuticals Inc. (RGO) stock is listed among top recommendationsWeekly Investment Report & Entry Point Confirmation Signals - newser.com
Published on: 2025-11-16 02:36:22 - newser.com
Can Regeneron Pharmaceuticals Inc. stock weather global recessionStop Loss & Growth Focused Investment Plans - newser.com
How currency fluctuations impact Regeneron Pharmaceuticals Inc. stockMarket Activity Recap & Accurate Intraday Trading Signals - newser.com
Regeneron Pharmaceuticals (NASDAQ:REGN) Rating Increased to Hold at Scotiabank - MarketBeat
Grandfield & Dodd LLC Boosts Stake in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Police & Firemen s Retirement System of New Jersey Has $8.34 Million Holdings in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
KBC Group NV Has $19.20 Million Position in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Regeneron Pharmaceuticals, Inc. $REGN Shares Sold by Banco Bilbao Vizcaya Argentaria S.A. - MarketBeat
How Regeneron Pharmaceuticals Inc. stock responds to policy changes2025 Pullback Review & AI Forecasted Entry/Exit Points - newser.com
A Look at Regeneron Pharmaceuticals’s (REGN) Valuation Following Recent Share Price Gains - simplywall.st
ABN Amro Investment Solutions Makes New Investment in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
How strong is Regeneron Pharmaceuticals Inc. stock balance sheetMarket Movers & Daily Volume Surge Trade Alerts - newser.com
Discipline and Rules-Based Execution in REGN Response - news.stocktradersdaily.com
Why Regeneron Pharmaceuticals Inc. stock is considered a top pickBreakout Watch & Safe Swing Trade Setups - newser.com
Regeneron's Saratoga Springs facility - The Post Star
Is Regeneron Pharmaceuticals Inc. stock positioned for digital transformationTrade Analysis Report & Expert-Curated Trade Recommendations - newser.com
What data driven models say about Regeneron Pharmaceuticals Inc.’s future2025 Volume Leaders & AI Powered Trade Plan Recommendations - newser.com
Regeneron Pharmaceuticals (NASDAQ:REGN) Now Covered by Analysts at Scotiabank - MarketBeat
Why millennials buy Regeneron Pharmaceuticals Inc. (RGO) stockMarket Volume Summary & Smart Investment Allocation Insights - newser.com
Biocon Challenges Regeneron Over UK Retinal Pharma Patent - Law360
Vise Technologies Inc. Takes $1.13 Million Position in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Pet Healthcare Spending Is Soaring. These Stocks Are Positioned to Clean Up - AOL.com
Geode Capital Management LLC Trims Position in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Regeneron Plans $2B Facility, Boosting Saratoga Economy - WGY
National Pension Service Boosts Stake in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Penserra Capital Management LLC Has $210,000 Stock Holdings in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Candriam S.C.A. Sells 72,733 Shares of Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Regeneron Pharmaceuticals, Inc. $REGN Shares Sold by Bailard Inc. - MarketBeat
CENTRAL TRUST Co Sells 1,069 Shares of Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Regeneron Pharmaceuticals Inc Stock (REGN) Financials Data
Revenue
Net Income
Cash Flow
EPS
5.51%
0.07%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):